Ginsenoside Rh2 Attenuates Post-Myocardial Infarction Heart Failure by Modulating the TGF-β/Smad2 Signaling Pathway
Ontology highlight
ABSTRACT: Background: Myocardial fibrosis and oxidative stress are key drivers of post-myocardial infarction heart failure (post-MI HF). Ginsenoside Rh2 (GRh2) has shown cardioprotective potential, but its role in post-MI HF and the underlying mechanism remain unclear. The current study aimed to investigate the therapeutic effect of GRh2 on post-MI HF and to validate its regulatory mechanism using murine, cellular, and cardiac organoid models. Methods: In vivo, Cardiac function and myocardial fibrosis were evaluated. Transcriptome analysis was performed to identify enriched signaling pathways. In vitro, H9C2 cardiomyocytes and cardiac organoids were subjected to oxygen-glucose deprivation (OGD). Cardiac injury indicators, fibrotic and oxidative stress markers, and proteins associated with the TGF-β/Smad2 pathway were measured via enzyme-linked immunosorbent assay (ELISA) and Western blotting. Results: In vivo, GRh2 treatment markedly improved cardiac function and reduced myocardial fibrosis in mice with post-MI heart failure. Transcriptomic analysis revealed that the TGF-β signaling pathway was substantially enriched. In vitro, GRh2 treatment significantly improved cell viability and reduced oxidative stress and fibrosis in OGD-exposed H9C2 cardiomyocytes and cardiac organoids. These protective effects were strongly associated with the suppression of the TGF-β/Smad2 signaling pathway. Conclusions: Ginsenoside Rh2 inhibits the TGF‑β/Smad2 signaling pathway to ameliorate cardiac dysfunction in post-MI heart failure, suggesting its potential as a therapeutic candidate.
ORGANISM(S): Mus musculus
PROVIDER: GSE348247 | GEO | 2026/09/30
REPOSITORIES: GEO
ACCESS DATA